High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Key Points Patient-specific pathways of resistance to venetoclax can be identified by high-content screening of clinical samples with a KI library. Sunitinib may overcome resistance to venetoclax for many patients by downregulating the expression of Bcl-xl, Mcl-1, and A1 in CLL cells.

authors

Oppermann, Sina
Ylanko, Jarkko
Shi, Yonghong
Hariharan, Santosh
Oakes, Christopher C
Brauer, Patrick M
Zúñiga-Pflücker, Juan C
Leber, Brian
Spaner, David E
Andrews, David W

status

published

publication date

August 18, 2016

has subject area

1102 Cardiorespiratory Medicine and Haematology (FoR)
1103 Clinical Sciences (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Adenine (MeSH)
Bridged Bicyclo Compounds, Heterocyclic (MeSH)
Cellular Microenvironment (MeSH)
Dose-Response Relationship, Drug (MeSH)
Drug Evaluation, Preclinical (MeSH)
Drug Resistance, Neoplasm (MeSH)
Humans (MeSH)
Imaging, Three-Dimensional (MeSH)
Immunology (Science Metrix)
Indoles (MeSH)
Leukemia, Lymphocytic, Chronic, B-Cell (MeSH)
Mutation (MeSH)
Piperidines (MeSH)
Protein Kinase Inhibitors (MeSH)
Purines (MeSH)
Pyrazoles (MeSH)
Pyrimidines (MeSH)
Pyrroles (MeSH)
Quinazolinones (MeSH)
Reproducibility of Results (MeSH)
Signal Transduction (MeSH)
Stromal Cells (MeSH)
Sulfonamides (MeSH)
Sunitinib (MeSH)
Up-Regulation (MeSH)
bcl-X Protein (MeSH)

published in

Blood Journal